Multiple myeloma–derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease
Jing Fu(Fourth People's Hospital of Sichuan Province), Suzanne Lentzsch(Columbia University Irving Medical Center)
Cited by 73
Related Papers
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
|Blood|2001|905
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
|The Lancet Oncology|2019|493
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
|The Lancet Oncology|2021|266
Targeting the Microtubular Network as a New Antimyeloma Strategy
|Molecular Cancer Therapeutics|2011|28
The checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease
|Nature Communications|2023|19